Clinical Trial

Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory rheumatoid arthritis. This study aims to evaluate the safety and efficacy of the treatment with Anti-CD19 CART.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-14.
Trial Details
NCT Number NCT06503237
Lead Sponsor The First Affiliated Hospital of University of Science and Technology of China
Conditions Rheumatoid Arthritis
Enrollment 18 participants
Start Date 2023-11-09
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-02-28